AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04409834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin SC
Description: Heparin 5,000 units administered subcutaneous three times daily
Study NCT04409834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg SC
Description: Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
Study NCT03551782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab 480 mg
Description: Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
Study NCT03551782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg
Description: Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
Study NCT04410861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse laser photostimulation
Description: In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
Study NCT04410861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse laser photostimulation
Description: In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
Study NCT03251521 — intervention group
Intervention type: OTHER
Intervention: pain rating during injection with botulinum toxin
Description: The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
Study NCT00960089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIQUICURE
Description: Topical treatment, 1 time/day, 5 days/week
Study NCT02563782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sub-retinal transplantation of MA09-hRPE cells
Description: transplantation
Study NCT02563782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus and mycophenolate mofetil
Description: Immunosuppressive Agents
Study NCT02563782 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo tacrolimus and mycophenolate mofetil
Description: placebo
Study NCT02563782 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Sham surgery
Study NCT03763747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoreflex NC Scoring PTCA catheter
Description: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
Study NCT00578097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
Study NCT00578097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection cycle, intradetrusor injection at baseline (visit 2).
Study NCT01523938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Pre- (one session) and postoperative (two sessions) Hypnotherapy
Study NCT02740465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Inventory for Respiratory Disease (AIR)
Description: An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
Study NCT02740465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
Study NCT01960491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Closure of Atrial Septal Defect
Description: Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder
Study NCT04270422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional physiotherapy
Description: Multidimensional physiotherapy based on biopsychosocial approach
Study NCT04270422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy
Description: Usual evidence based physiotherapy
Study NCT02900014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sampling mesenchymal stem cells
Description: nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
Study NCT02403596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo of Exacyl®
Study NCT02403596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Exacyl®
Study NCT01926678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish massage therapy
Study NCT01926678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Swedish massage therapy
Study NCT01926678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light touch therapy
Study NCT01926678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Light touch therapy
Study NCT01574807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepivacaine + lidocaine followed by lidocaine +lidocaine
Description: 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Study NCT01574807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine + lidocaine followed by mepivacaine + lidocaine
Description: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Study NCT01499771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 Mg tablets
Study NCT01499771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 Mg tablets
Study NCT03174171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 0.75 mg
Description: Everolimus 0.75 mg b.i.d. orally for 14 days.
Study NCT00705588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Orally, titrated to maximum 20mg od
Study NCT00705588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Orally, titrated to 10 mg bid
Study NCT00823225 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard therapy
Description: wound debridement, moist wound dressing
Study NCT00823225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase
Description: Daily infusion up to 21 applications, dose dependent on fibrinogen level:~> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU
Study NCT01617187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Asenapine
Description: Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
Study NCT04356430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
Study NCT04356430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg oral low dose prednisone, once daily
Study NCT04356430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg
Description: 10.8 mg goserelin hypodermic once per 12 weeks
Study NCT01617187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Asenapine
Description: Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
Study NCT01617187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
Study NCT01617187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
Study NCT01617187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Olanzapine
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
Study NCT01617187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Olanzapine
Description: Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
Study NCT03481127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated psychological care
Description: Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
Study NCT03481127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: * NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey
Study NCT03481127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: * NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey
Study NCT03481127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment
Study NCT03481127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment
Study NCT03481127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh tissue from ovary
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery
Study NCT03481127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh tissue from ovary
Description: * For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery
Study NCT05123651 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus rhamnosus X253
Description: Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
Study NCT03977701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morpheme treatment
Description: The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
Study NCT00988936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]RGD-K5
Description: Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
Study NCT05123651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus X253
Description: Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
Study NCT03360136 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multi-professional CBT-rehabilitation
Description: See Detailed description
Study NCT02067091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent implant in a coronary artery
Description: Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention
Study NCT02352805 — intervention group
Intervention type: DEVICE
Intervention: ECLS/ECC
Description: Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
Study NCT02636296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
Study NCT02636296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
Study NCT03586947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 400 UNT Oral Capsule
Description: 50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
Study NCT03305484 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observation only
Study NCT00984503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
Study NCT00984503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
Study NCT00984503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
Study NCT00984503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
Study NCT03340714 — intervention group
Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wear ADAMM
Study NCT04284709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-physical training
Description: combined physical and cognitive training
Study NCT04284709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive-physical training
Description: combined physical and cognitive training
Study NCT01126957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine was given as a 0.5mg / Kg bolus.
Study NCT01126957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given as an bolus to control group.
Study NCT01126957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
Study NCT01126957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
Study NCT01126957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol given to both arms to maintain sedation throughout procedure.
Study NCT01013896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
Study NCT01013896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cystic Fibrosis Education
Description: Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group.
Study NCT02997384 — intervention group
Intervention type: OTHER
Intervention: Information
Description: information of women about their risk of breast cancer and the screening methods recommended for them
Study NCT01929655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
Study NCT04065087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Investigational drug
Study NCT04065087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study NCT02518152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by Open flap debridement (OFD)
Study NCT02518152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
Study NCT02518152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1% Alendronate
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
Study NCT02247284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNFL and BMO-MRW SD-OCT
Description: Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
Study NCT01126957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol given to both arms to maintain sedation throughout procedure.
Study NCT05600413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: 4 weeks of L-Citrulline supplementation (6 grams/day)
Study NCT01924052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP
Description: Calcitonin-gene-related-peptide (CGRP)
Study NCT02935114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37% Carbamide Peroxide
Description: * no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation
Study NCT02935114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 35% hydrogen Peroxide
Description: * Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation
Study NCT04753814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagostic tests
Description: Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
Study NCT00645294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir dipivoxil
Description: 0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
Study NCT00645294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir Dipivoxil
Description: 0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
Study NCT00645294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir Dipivoxil
Description: ADV 10 mg on Day 1